

Blue Jet Healthcare

Estimate changes



TP change



Rating change

CMP: INR481

TP: INR580 (+20%)

Buy

Pharma destocking hurts performance; FY27 recovery likely

Earnings above our estimates

Bloomberg	BLUEJET IN
Equity Shares (m)	173
M.Cap.(INRb)/(USDb)	83.5 / 0.9
52-Week Range (INR)	1028 / 325
1, 6, 12 Rel. Per (%)	19/-8/-37
12M Avg Val (INR M)	388

Financial Snapshot (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	9.5	11.1	12.7
EBITDA	2.9	3.5	4.1
PAT	2.5	2.8	3.4
EPS (INR)	14.3	16.3	19.3
EPS Gr. (%)	-18.8	14.0	18.5
BV/Sh.(INR)	78.4	93.6	111.6

Ratios

Net D:E	-0.1	-0.0	-0.1
RoE (%)	19.9	18.9	18.8
RoCE (%)	20.1	18.7	18.6
Payout (%)	6.8	6.8	6.8

Valuations

P/E (x)	33.8	29.6	25.0
P/BV (x)	6.2	5.2	4.3
EV/EBITDA (x)	28.0	23.9	19.8
Div. Yield (%)	0.2	0.2	0.3
FCF Yield (%)	1.9	-2.7	1.8

Shareholding pattern (%)

As of	Mar-26	Dec-25	Mar-25
Promoter	79.8	79.8	86.0
DII	4.5	4.6	1.3
FII	0.9	1.1	2.3
Others	14.8	14.4	10.4

FII includes depository receipts

- Blue Jet Healthcare (BLUEJET) reported revenue of INR2.3b in 4Q, down 31% YoY, primarily due to pharma intermediate (PI) destocking (revenue down 99% YoY). This was partially offset by the healthy performances of contrast media/high-intensity sweeteners (up 91%/24% YoY).
- However, we expect the pharma intermediates segment to recover in FY27, boosted by improving shipment trends, normalization after industry-wide destocking, and strong visibility in select programs. This will be further supported by management guidance of double-digit growth in the contrast media segment on the back of new launches.
- Factoring in recovery in the PI segment and management guidance, we raise our FY27/FY28 earnings estimates by 14% each. We value the stock at 30x FY28E EPS to arrive at our TP of INR580. **Reiterate BUY.**

Sequential recovery led by contrast media

- BLUEJET reported revenue of INR2.3b in 4Q, down 31% YoY but up 22% QoQ (est. INR1.9b). High-intensity sweeteners/contrast media intermediates' revenue grew 24%/91% YoY to INR368m/INR1.9b, while revenue from pharma intermediates declined 99% YoY to INR24m.
- Gross margin stood at 56.4% (+150bp YoY, +470bp QoQ), aided by rupee depreciation and pass-through of higher costs to a few customers.
- As a percentage of sales, employee costs stood at ~8% (vs. ~5% in 4QFY25), while other expenses stood at ~18% (vs. ~9% in 4QFY25).
- EBITDA stood at INR713m (est. INR476m), down 49% YoY, but up 52% QoQ. EBITDA margin was 30.4% (-10.7pp YoY, +600bp QoQ).
- Adj. PAT stood at INR643m (down 42% YoY, up 60% QoQ), above our estimate of INR419m.
- For FY26, its revenue/EBITDA/Adj PAT declined 9%/22%/19% YoY to INR9.5b/INR2.9b/INR2.5b. CFO stood at INR3.3b vs INR458m as of Mar'25.
- The company's NWC improved by 5 days YoY to 181. This was led by a 22-day reduction in inventory, which was partially offset by a 7-day increase in receivables and a 10-day dip in payables.

Highlights from the management commentary

- Capex and expansion strategy:** Project activities have commenced for the Vizag project, which is expected to entail a capex outlay of INR10b over the next three years. Further, construction of the R&D center in Hyderabad is likely to be completed by Sep'26, entailing a capex of INR400m. The facility will focus on development activities related to peptides and GLP-1 opportunities. Further, management guided a capex of INR4b in FY27.
- Pharma Intermediaries (PI):** Management is factoring in improvements driven by inventory normalization and better order visibility. Further, the company expects **FY27 sales to surpass the peak revenue levels achieved in FY25.**


- **Advanced contrast media:** The company derived the majority of its revenue from existing products and customers in 4QFY26. The New Chemical Entity (NCE) molecule commercialized in FY25 witnessed strong offtake during FY26, with the momentum expected to continue in the near term. Further, customer engagements for FY27 remain encouraging, indicating double-digit growth driven by volume expansion and new product launches.
- **CDMO pipeline:** Lab-scale supplies for intermediates related to GLP-1 and peptide products have commenced and are expected to transition into the commercialization phase in FY27. Further, the company plans to adopt a phased approach in peptides, initially focusing on manufacturing peptide building blocks and fragments. Over time, as BLUEJET expands its expertise and customer base, it intends to move towards manufacturing complete peptides, supported by planned capacity creation at its Vizag facility.

Valuation and view


- We anticipate a recovery in pharma intermediates in FY27, led by the end of destocking. Growth is likely to be supported by strong momentum in contrast media through new launches, NCE molecule commercialization, backward integration, and capacity expansion, alongside recovery in pharma intermediates supported by healthy order visibility and new opportunities.
- Further, ongoing investments in Vizag, Hyderabad, and CDMO capabilities are expected to support the company's next phase of commercialization-led growth.
- We expect a CAGR of 16%/19%/16% in revenue/EBITDA/PAT over FY26-28. Factoring in recovery in the PI segment and management guidance, we raise our FY27/FY28 earnings estimates by 14% each. We value the stock at 30x FY28E EPS to arrive at our TP of INR580. **Reiterate BUY.**

Standalone - Quarterly Snapshot


Y/E March	FY25				FY26				(INR m)			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY25	FY26	FY26 4QE	Var. (%)
Gross Sales	1,629	2,083	3,174	3,404	3,548	1,655	1,924	2,347	10,290	9,473	1,959	20%
YoY Change (%)	-9.3	14.8	90.3	85.1	117.8	-20.5	-39.4	-31.1	44.6	-7.9	-42.5	
Gross Margin (%)	54.7%	57.0%	54.5%	54.9%	48.4%	65.0%	51.7%	56.4%	55.2%	54.0%	51.0%	
EBITDA	443	695	1,230	1,400	1,210	549	469	713	3,767	2,941	476	50%
Margin (%)	27.2	33.4	38.8	41.1	34.1	33.2	24.4	30.4	36.6	31.0	24.3	
Depreciation	35	46	47	49	57	59	60	65	178	240	63	
Interest	0	0	0	0	7	46	3	6	1	62	5	
Other Income	87	121	132	122	83	243	132	229	463	687	140	
PBT before EO expense	495	769	1,315	1,472	1,229	687	538	871	4,051	3,325	548	
Extra-Ord expense	0	0	0	0	0	0	0	0	0	0	0	
PBT	495	769	1,315	1,472	1,229	687	538	871	4,051	3,325	548	
Tax	117	186	335	371	317	166	136	228	1,009	847	129	
Rate (%)	23.6	24.1	25.5	25.2	25.8	24.1	25.3	26.2	24.9	25.5	23.5	
Reported PAT	378	583	980	1,101	912	521	402	643	3,042	2,478	419	
Adj. PAT	378	583	980	1,101	912	521	402	643	3,042	2,478	419	53%
YoY Change (%)	-14.4	21.9	149.5	177.6	141.3	-10.6	-59.0	-41.6	77.9	-18.5	-61.9	
Margin (%)	23.2	28.0	30.9	32.3	25.7	31.5	20.9	27.4	29.6	26.2	21.4	

Story in charts
Exhibit 1: Revenue declined 39% YoY



Source: Company, MOFSL

Exhibit 2: EBITDAM contracted on a YoY basis


Source: Company, MOFSL


Exhibit 3: EBITDA declined 49% YoY


Source: Company, MOFSL

Exhibit 4: Quarterly PAT trend



Source: Company, MOFSL

Exhibit 5: Revenue of CM grew 91% YoY




Source: Company, MOFSL

Exhibit 6: High-intensity sweetener sales grew 24% YoY




Source: Company, MOFSL

Exhibit 7: PI down 99% YoY




Source: Company, MOFSL

Exhibit 8: Other sales down 90% YoY



Source: Company, MOFSL

Exhibit 9: Segmental contribution to total revenue (%)



Source: Company, MOFSL



Key highlights from the management commentary

Operational performance

- FY26 was a mixed operating environment
- Rupee depreciation improved export realizations. Discussions based on price pass-throughs are positive with the customers.

FY27 outlook

- Freight costs post Mar'26 have increased, which would affect FY27. Management is monitoring the environment, and 1QFY27 will be a good representation of the cost structure. The domino effect on the industry due to the West Asa conflict.
- The company is anticipating a recovery in Intermediaries supported by improved shipments. Further, the company is targeting double-digit growth from the Advanced contrast media segment.

Capex and expansion strategy

- The ground-breaking ceremony of the Vizag project was completed, and project activities have commenced. Long-term growth platform being developed in a phased manner for APIs and Intermediates. Scale and strategic location to help position Blue Jet as a reliable supplier
- The company is planning dedicated blocks of Contrast Media Intermediates and High Intensity Sweeteners for phase 1. Capex of INR10b spent over three years, with ~24-30 months for capacity to get in line.
- FY27 will be investment-intensive, which will support the next phase of growth for the company. The commercialization growth cycle will commence soon.
- Civil construction of R&D center in Hyderabad commenced and is expected to be completed by Sep'26 with expected capex of INR400m. Hiring of key resources initiated. Development work will include peptides and GLP-1-linked opportunities.
- CWP of INR3b relating to Mahad and investment in Vizag (land acquisitions). Mahad Unit is expected to commence production in 2HFY27
- INR4b capex in FY27 comprising the Vizag project, additions in Ambarnath, and completion of the Mahad unit

Pharma intermediates (PI)

- PI destocking and inventory normalization completed by the customer. Robust revenues are expected, backed by orders from this segment in the coming quarter, supported by order visibility. Normalization is expected to exceed the peak sales, which were achieved in FY25.
- Orders are already in hand, and shipments have already started supporting strong revenue visibility from this segment in FY27.
- Molecule bempedoic is still under patent; there are not a great number of suppliers in the market for this. Once the patent expires, markets will be filled with suppliers. Bempedoic is a very advanced intermediate because of the complexities and regulatory pathways. Competitive edge due to chemistry, dedicated plant, unit operations have been doing well, and the scale

- Customer engagement and capacity readiness will position the company as a strong player.

Advanced Contrast Media

- The company received trial orders in Advanced Contrast Media from a new Japanese customer.
- Key molecules in the existing partnership are being deepened. The majority of revenue from existing products and customers in 4QFY26
- Customer engagements have been positive for FY27, which indicates **double-digit** growth is expected (volume growth and new launches). The company is anticipating 2 validations and one new commercialization.
- The lateral entries volume would turn out faster.
- Customer offtakes are promising. CDMO should be looked at annually and not quarterly. Goods in transit have normalized. Entire revenue of ~INR1.9b in 4QY26 was from 4th quarter orderbook
- NCE molecule commercialized in FY25 saw strong offtake in FY26, which is expected to continue in the near term. Some contribution from a select molecule in FY26
- 3-4 new products will be launched in FY27
- The company is far from capacity maximization

Backward Integration through the Mahad unit

- Mahad Unit 3 backward integration is progressing well, comprising three Raw Materials utilized in the Contrast Media portfolio, which will help to mitigate RM disruption.
- The plant is expected to commence operations in 2HFY27, with the full benefit of backward integration expected from FY28.
- After some periods, output will be sold to 3rd parties and not just be used for internal consumption.
- Imports from Europe and China are expected to reduce due to the Mahad unit.

High Intensity Sweeteners

- High-volume product currently under validation, with trial quantities expected to be shipped in the coming quarters
- Pricing pressures due to imports
- If the key validation is met, then it would be significant for the company

CDMO pipeline

- Intermediates related to GLP-1 and peptides will move to the commercialization phase in FY27. Lab supplies are being provided to some innovators and peptide manufacturers.
- Initially, the company will manufacture peptide fragments that form peptides at Vizag, and eventually produce the final peptide. Price erosion is a risk in the peptides business.
- Gestation of 3-4 years; doubling capacities and R&D will help the company going forward.
- CDMO Pharma Intermediates is showing fantastic growth at advanced stages

Other

- The company has a 51-commercialized portfolio as of FY26
- ~70% of the company's power requirements are from renewable sources
- Mid-single-digit growth expected from end customers
- Other income increased due to exchange gains and an insurance claim (INR50m)
- Chemistry and a highly automated plant

Valuation and view

- We anticipate a recovery in pharma intermediates in FY27, led by the end of destocking. Growth is likely to be supported by strong momentum in contrast media through new launches, NCE molecule commercialization, backward integration, and capacity expansion, alongside recovery in pharma intermediates supported by healthy order visibility and new opportunities.
- Further, ongoing investments in Vizag, Hyderabad, and CDMO capabilities are likely to support the company's next phase of commercialization-led growth.
- We expect a CAGR of 16%/19%/16% in revenue/EBITDA/PAT over FY26-28. Factoring in recovery in the PI segment and management guidance, we raise our FY27/FY28 earnings estimates by 14% each. We value the stock at 30x FY28E EPS to arrive at our TP of INR580. **Reiterate BUY.**

Exhibit 10: Changes to our estimates (INR m)

Particulars	Revised		Previous		Change (%)	
	FY27	FY28	FY27	FY28	FY27	FY28
Revenue (INR m)	11,096	12,713	10,099	11,672	10%	9%
EBITDA (INR m)	3,497	4,134	3,080	3,684	14%	12%
PAT (INR m)	2,826	3,350	2,469	2,951	14%	14%
EPS (INR)	16.3	19.3	14.2	17.0	14%	14%

Financials and valuations

Standalone - Financial Snapshot

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	4,989	6,835	7,210	7,116	10,300	9,473	11,096	12,713
Change (%)	-7.3	37.0	5.5	-1.3	44.7	-8.0	17.1	14.6
Gross Margin (%)	66.0	57.9	53.4	55.8	55.2	54.0	53.8	54.4
EBITDA	2,061	2,404	2,280	2,292	3,777	2,941	3,497	4,134
Margin (%)	41.3	35.2	31.6	32.2	36.7	31.0	31.5	32.5
Depreciation	197	221	251	281	178	240	277	332
EBIT	1,864	2,183	2,029	2,011	3,599	2,701	3,220	3,803
Int. and Finance Charges	53	33	14	2	1	62	60	40
Other Income	89	194	240	289	463	687	617	714
PBT bef. EO Exp.	1,900	2,344	2,255	2,298	4,061	3,325	3,777	4,477
EO Items	-53	0	0	-97	0	0	0	0
PBT after EO Exp.	1,847	2,344	2,255	2,201	4,061	3,325	3,777	4,477
Total Tax	488	616	566	563	1,009	847	951	1,127
Tax Rate (%)	26.4	26.3	25.1	25.6	24.8	25.5	25.2	25.2
Reported PAT	1,358	1,727	1,689	1,638	3,052	2,478	2,826	3,350
Adjusted PAT	1,397	1,727	1,689	1,710	3,052	2,478	2,826	3,350
Change (%)	-3.4	23.6	-2.2	1.2	78.5	-18.8	14.0	18.5
Margin (%)	28.0	25.3	23.4	24.0	29.6	26.2	25.5	26.4

Standalone - Balance Sheet

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	99	347	347	347	347	347	347	347
Total Reserves	3,299	4,868	6,468	8,105	10,984	13,252	15,886	19,007
Net Worth	3,398	5,215	6,815	8,452	11,331	13,599	16,233	19,354
Total Loans	516	173	34	0	0	0	600	0
Deferred Tax Liabilities	14	3	10	32	73	106	106	106
Capital Employed	3,928	5,391	6,859	8,484	11,404	13,705	16,939	19,460
Gross Block	1,636	1,855	2,431	2,921	4,382	4,784	5,284	6,784
Less: Accum. Deprn.	448	670	920	1,201	1,379	1,619	1,896	2,228
Net Fixed Assets	1,188	1,185	1,510	1,719	3,003	3,164	3,387	4,556
Goodwill on Consolidation	201	380	0	0	0	0	0	0
Capital WIP	26	34	305	1,471	892	3,014	6,514	6,014
Total Investments	368	938	1,893	2,505	1,867	252	252	252
Curr. Assets, Loans&Adv.	3,579	4,595	4,913	4,894	8,413	9,982	10,201	12,552
Inventory	1,177	1,050	1,257	1,298	2,639	1,874	2,195	2,515
Account Receivables	1,440	2,274	2,394	1,769	3,495	3,390	3,891	4,458
Cash and Bank Balance	705	877	656	847	1,198	1,489	786	1,765
Cash	611	754	654	410	330	621	-82	897
Bank Balance	93	123	2	438	868	868	868	868
Loans and Advances	258	393	606	979	1,081	3,229	3,329	3,814
Curr. Liability & Prov.	1,435	1,741	1,761	2,104	2,771	2,706	3,415	3,913
Account Payables	595	565	538	303	891	569	912	1,045
Other Current Liabilities	802	1,132	1,177	1,749	1,820	2,057	2,409	2,760
Provisions	37	43	46	52	60	80	94	108
Net Current Assets	2,145	2,854	3,151	2,789	5,642	7,276	6,786	8,639
Misc Expenditure	0	0	0	0	0	0	0	0
Appl. of Funds	3,928	5,391	6,859	8,484	11,404	13,705	16,939	19,460

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)								
EPS	28.2	10.0	9.7	9.9	17.6	14.3	16.3	19.3
EPS Growth (%)	-3.4	-64.7	-2.2	1.2	78.5	-18.8	14.0	18.5
Cash EPS	32.2	11.2	11.2	11.5	18.6	15.7	17.9	21.2
BV/Share	68.6	30.1	39.3	48.7	65.3	78.4	93.6	111.6
DPS	0.0	0.0	0.0	1.0	1.2	1.0	1.1	1.3
Payout (%)	0.0	0.0	0.0	10.6	6.8	6.8	6.8	6.8
Valuation (x)								
P/E	17.1	48.5	49.6	48.9	27.4	33.8	29.6	25.0
Cash P/E	15.0	43.0	43.1	42.0	25.9	30.8	27.0	22.7
P/BV	7.0	16.0	12.3	9.9	7.4	6.2	5.2	4.3
EV/Sales	4.8	12.1	11.5	11.6	8.0	8.7	7.5	6.4
EV/EBITDA	11.5	34.5	36.4	36.1	21.8	28.0	23.9	19.8
Dividend Yield (%)	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.3
FCF per share	19.6	7.2	4.7	4.0	-1.9	6.6	-9.6	6.5
Return Ratios (%)								
RoE	51.9	40.1	28.1	22.4	30.9	19.9	18.9	18.8
RoCE	44.4	37.6	27.7	22.3	30.7	20.1	18.7	18.6
RoIC	53.2	50.5	40.3	39.0	48.7	24.6	26.3	27.3
Working Capital Ratios								
Fixed Asset Turnover (x)	4.5	5.8	5.4	4.4	4.4	3.1	3.4	3.2
Asset Turnover (x)	1.3	1.3	1.1	0.8	0.9	0.7	0.7	0.7
Inventory (Days)	86	56	64	67	94	72	72	72
Debtor (Days)	105	121	121	91	124	131	128	128
Creditor (Days)	44	30	27	16	32	22	30	30
Leverage Ratio (x)								
Current Ratio	2.5	2.6	2.8	2.3	3.0	3.7	3.0	3.2
Interest Cover Ratio	35.1	66.1	149.3	1,249.3	3,672.9	43.3	53.7	95.1
Net Debt/Equity	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	0.0	-0.1

Standalone - Cash Flow Statement

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	1,847	2,432	2,166	2,201	4,061	3,325	3,777	4,477
Depreciation	197	221	251	281	178	240	277	332
Interest Expenses	0	0	0	2	1	62	60	40
Others	-21	-154	-73	-91	-264	-288	-617	-714
Direct Taxes Paid	-2	-276	-600	-111	-890	-1,088	-951	-1,127
(Inc)/Dec in WC	-727	-759	-329	132	-2,628	1,090	-213	-875
CF from Operations	1,293	1,464	1,415	2,413	458	3,341	2,333	2,133
CF from Operating incl EO								
(Inc)/Dec in FA	-321	-218	-593	-1,722	-795	-2,195	-4,000	-1,000
Free Cash Flow	972	1,247	823	691	-337	1,147	-1,667	1,133
Change in Investments	27	15	4	-906	391	-502	0	0
Others	-213	-557	-884	-10	52	-59	617	714
CF from Investments	-507	-760	-1,473	-2,638	-352	-2,756	-3,383	-286
Issue of Shares	0	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-222	-526	0	0	0	0	600	-600
Interest Paid	-53	-32	0	-2	-1	-47	-60	-40
Dividend Paid	0	0	0	0	-173	-208	-193	-228
Others	94	119	-40	419	857	828	0	0
CF from Fin. Activity	-182	-439	-40	418	683	573	347	-868
Inc/Dec of Cash	604	266	-98	193	789	1,159	-702	979
Opening Balance	100	611	754	654	410	330	1,489	786
Closing Balance	705	877	656	848	1,198	1,489	786	1,765

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company
 actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 received compensation/other benefits from the subject company in the past 12 months
 any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 Served subject company as its clients during twelve months preceding the date of distribution of the research report.
 The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
 Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
Analyst Certification
 The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.
Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CD SL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.